OCUL Ocular Therapeutix
- 5.490
- -0.010-0.18%
Ocular Therapeutix News
Sector Update: Health Care Stocks Decrease Late Afternoon
Health care stocks were softer late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) edging down 0.1%. The iShares Biotechnology ETF (IBB)
Ocular Therapeutix Shares Soar 13% Following Clinical Development Progress Report
Ocular Therapeutix (OCUL) shares were up nearly 15% in recent Friday trading after the company reported its clinical development progress at its investor day Thursday. The company said it had enrolled
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for
Express News | Piper Sandler Maintains Overweight on Ocular Therapeutix, Maintains $15 Price Target
Express News | Ocular Therapeutix Shares Are Trading Higher Following Comments and Updates at Thursday's Investor Day Event
Ocular Therapeutix Shares Rise 19% After Positive Data From Axpaxli Study
Ocular Therapeutix shares were up 19% to $6 after the company said it saw excellent clinical development progress with Axpaxli for wet age-related macular degeneration and non-proliferative diabetic retinopathy.
Hasbro, Tutor Perini, Arm Holdings And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly lower, with the Dow Jones index falling around 300 points on Friday.Shares of Hasbro, Inc. (NASDAQ:HAS) rose sharply during Friday's session after B of A Securities upgraded th
A Quick Look at Today's Ratings for Ocular Therapeutix(OCUL.US), With a Forecast Between $7 to $22
On Jun 14, major Wall Street analysts update their ratings for $Ocular Therapeutix(OCUL.US)$, with price targets ranging from $7 to $22.TD Cowen analyst Tara Bancroft maintains with a hold rating, and
Express News | HC Wainwright & Co. Reiterates Buy on Ocular Therapeutix, Maintains $14 Price Target
Ocular Therapeutix Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/14/2024 173.44% HC Wainwright & Co. $14 → $14 Reiterates Buy → Buy 05/08/2024 173.44% HC Wainwright & C
Ocular Therapeutix Highlights Exceptional AXPAXLI SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in Wet AMD at Investor Day, Along With Positive 48-week Data From HELIOS NPDR Study
Express News | Ocular Therapeutics Announces 80% Rescue-Free Rate In U.S. Wet AMD Study, Promising Diabetic Retinopathy Results, And FDA Special Protocol Assessment For SOL-one Study; Highlights Significant Market Potential And Strong Team Of Retina Experts
Express News | Watching Shares Of Ocular Therapeutix, Company Presenting At Their Investor Day
Is Ocular Therapeutix, Inc. (NASDAQ:OCUL) Trading At A 45% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Ocular Therapeutix fair value estimate is US$9.56 Ocular Therapeutix's US$5.30 share price signals that it might be 45% undervalued Analys
An Intrinsic Calculation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Suggests It's 45% Undervalued
Ocular Therapeutix to Host Investor Day on June 13, 2024
Company to highlight corporate strategy, clinical data, and development plans for AXPAXLI in wet AMD and NPDR Event to feature prominent retinal disease experts Baruch D. Kuppermann, MD, PhD (University of
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a biopharmaceutical company committed to enhancing people's vision and quality of life through the development and
Ocular Therapeutix Cutting 13% of Workforce
Ocular Therapeutix (OCUL) said Monday its board has approved a reduction of 37 full-time employees, or about 13% of its workforce. The job cuts will affect mainly the company's research and developmen
Express News | Ocular Therapeutix Announces Strategic Reduction In Force, Eliminates 37 Employees, Or 13% Of Workforce, To Focus On AXPAXLI Clinical Development For Wet Age-Related Macular Degeneration
Express News | Ocular Therapeutix Sees Total Restructuring Costs of About $1.0 to $2.0 Mln
Analysis
Price Target
No Data
